医学临床研究
醫學臨床研究
의학림상연구
JOURNAL OF CLINICAL RESEARCH
2009年
7期
1234-1235
,共2页
脑血管意外/并发症%抑郁症/药物疗法%抗抑郁药/治疗应用
腦血管意外/併髮癥%抑鬱癥/藥物療法%抗抑鬱藥/治療應用
뇌혈관의외/병발증%억욱증/약물요법%항억욱약/치료응용
cerebrovascular disorders/CO%depression/DT%antidepressive agents/TU
[目的]观察文拉法辛治疗脑卒中后抑郁(PSD)患者的疗效和不良反应.[方法]72例PSD患者分为文拉法辛组和阿米替林组各36例,于治疗前及治疗后第2周,第4周,第6周对两组患者进行hamilion抑郁量表(HAMD)和副反应量表(TESS)评定.[结果]治疗后,两组患者的HAMD评分均较治疗前明显降低(P<0.01),但两组间无显著差异(P>0.05),文拉法辛组的不良反应明显较阿米替林组少且轻(P<0.01).[结论]文拉法辛治疗PSD安全,有效.
[目的]觀察文拉法辛治療腦卒中後抑鬱(PSD)患者的療效和不良反應.[方法]72例PSD患者分為文拉法辛組和阿米替林組各36例,于治療前及治療後第2週,第4週,第6週對兩組患者進行hamilion抑鬱量錶(HAMD)和副反應量錶(TESS)評定.[結果]治療後,兩組患者的HAMD評分均較治療前明顯降低(P<0.01),但兩組間無顯著差異(P>0.05),文拉法辛組的不良反應明顯較阿米替林組少且輕(P<0.01).[結論]文拉法辛治療PSD安全,有效.
[목적]관찰문랍법신치료뇌졸중후억욱(PSD)환자적료효화불량반응.[방법]72례PSD환자분위문랍법신조화아미체림조각36례,우치료전급치료후제2주,제4주,제6주대량조환자진행hamilion억욱량표(HAMD)화부반응량표(TESS)평정.[결과]치료후,량조환자적HAMD평분균교치료전명현강저(P<0.01),단량조간무현저차이(P>0.05),문랍법신조적불량반응명현교아미체림조소차경(P<0.01).[결론]문랍법신치료PSD안전,유효.
[Objective] To observe the efficacy and side effects of venlafaxine in the treatment of post-stroke depression (PSD). [Methods] Seventy two patients with PSD were randomly divided into venlafaxine group(n=36) and amitriptyline group(n=36). Before the treatment and at the end of 2nd, 4th and 6th week after the treatment, all patients in two groups were assessed with Hamilton Depression Scale (HAMD) and TESS. [Results] After treatment, HAMD scores of patients of two groups were decreased significantly(P<0.01), but no difference was found between two groups (P>0.05). The side effects of the venlafaxine group were obviously fewer and milder than those of amitriptyline group (P<0.01). [Conclusion] Venlafaxine is an effective and safe drug in the treatment of PSD.
